Liposarcoma Treatment Market 2022
The conventional practices are being augmented through robotic, AI-driven systems, thereby taking the past as well as the present to the future. This would, in the true sense, let clinicians carve cutting-edge technologies and implement them in proper ways, and avert the probable risks. This would be the scene with the Liposarcoma Treatment Market in the upcoming decade.
Liposarcoma is a cancer of fat cells lying deep within the soft tissues, typically in retroperitoneum or thighs. According to WHO, liposarcoma is the most common type of sarcomas (cancer of soft tissue) and accounts for approximately 17-20% of all cases of sarcoma. However, WHO classifies liposarcoma in the rare diseases as the incidence rate of the disease is as low as 2.5 per Mn population.
Liposarcoma most commonly occurs in the middle age or adults above the age of 40 and it can be well diagnosed with the help of excision biopsy. Liposarcoma can be of four types viz. well differentiated liposarcoma, myxoid liposarcoma, pleomorphic liposarcoma and dedifferentiated liposarcoma. The most common drugs used for the treatment of liposarcoma include ifosfamide and doxorubicin.
Ifosfamide is often prescribed in combination with uromitexan in order to prevent bladder irritation and internal bleeding. Moreover, cisplatin, vincristine, etoposide, gemcitabine, docetaxel etc. can be used to prevent the recurrence of liposarcoma.
Get Free Sample Copy of this Report @ https://www.persistencemarketresearch.com/samples/10109
Market Segmentation
Based on treatment type
- Chemotherapy
- Radiation Therapy
- Surgical Therapy
Based on the end user type
- Hospitals
- Multispecialty Clinics
- Cancer treatment and rehabilitation centers
Based on geography
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
For entire list of market players, request for Table of content here @ https://www.persistencemarketresearch.com/toc/10109
Surgical therapy treatment segment is expected to account for major share in global liposarcoma treatment market as it is the choice of treatment recommended by majority of cancer specialists.
Most of the physicians do not rely on chemotherapy for the liposarcoma treatment however, it can be used prior to the surgery to reduce the size of the tumor making it the second largest segment in terms of value in global liposarcoma treatment market. Radiation therapy treatment is used to avoid recurrence of the liposarcoma after surgery and contributes a minimal share in global liposarcoma treatment market.
North America is anticipated to lead the global liposarcoma treatment market due to relatively greater prevalence of the disease in the region. APAC and MEA regions are expected to witness steady market growth owing to lack of awareness about the disease.
Pre-Book Right Now for Exclusive Analyst Support @ https://www.persistencemarketresearch.com/checkout/10109
Some of the key players in global liposarcoma treatment market include Eli Lilly and Company, Baxter International, Bristol Laboratories Ltd., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Actavis plc.,Fresenius Kabi Ltd., Accord Healthcare Inc., Taro Pharmaceuticals Inc., Sandoz, Bedford Laboratories and others. Recently FDA approved the new indication of Halaven (eribulin) to Esai Co. Ltd. and new drug application of Yondelis (Trabectedin) from Johnson & Johnson Private Limited for use in Europe, Russia and South Korea.
About Us: – Persistence Market Research
Contact us:
Persistence Market Research
Address – 305 Broadway, 7th Floor New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com